ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
DSM is considering strategic options—including divestment—of its polymer intermediates business, which manufactures composite resins, caprolactam, and acrylonitrile. The unit has annual sales of about $1.9 billion. The move follows pressure from the activist hedge fund Third Point, which has taken a stake in DSM and wants to see the firm broken up. Third Point is similarly targeting Dow Chemical. The pretax profits of the polymer intermediates business fell $6 million, to $29 million, for the third quarter of 2014.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X